2022 Clinical Trials Safety Sleep 
TheAnswerPage
FEBRUARY 23, 2022
Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). What are the common adverse events noted in clinical trials examining the efficacy of cannabinoids for ASD? Fletcher S.
Cannabis Law Report
JULY 13, 2022
VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. ( Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
OCTOBER 29, 2021
(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The primary endpoint of this Phase 1 trial was safety and tolerability.
The Cannigma
DECEMBER 12, 2022
Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. Iboga safety: Numerous concerns about the safety of iboga have been raised by scientists.
Project CBD
FEBRUARY 28, 2023
Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. Available at: [link] Accessed October 17, 2022. Accessed October 17, 2022. February 2, 2022.
The Cannigma
JANUARY 13, 2023
The ECS touches on nearly every biological function you have, including sleep, pain, appetite, body temperature, immune function, memory, and hormone regulation. While migraines are a commonly reported condition by patients in cannabis studies, there is little clinical research on how cannabis can influence migraine pain.
Cannabis Law Report
DECEMBER 7, 2021
The four-week Institutional Review Board (IRB) approved randomized controlled trial (RCT) of nearly 3,000 participants assigned to different botanical products containing CBD revealed significant improvement across all five health outcomes studied: well-being, quality of life, longer-term pain, feelings of anxiety, and sleep quality.
Expert insights. Personalized for you.
52 
Let's personalize your content